

I

wherein:

m and n are the same or different and each is an integer from 2-8;

R is a cationic group or  ;

X_1 is a member selected from the group consisting of



and



;

and X_2 and X_3 are each independently selected from the group consisting of a saccharide,



and



;

and, wherein at least one of X_2 and X_3 is a saccharide group when R is  .

62. (New) The method of claim **61**, wherein said adenoviral vector is selected from the group consisting of a replication competent viral vector, a replication deficient viral vector and a conditionally replicating viral vector.

63. (New) The method of claim **61**, wherein said tumor suppressor gene is selected from the group consisting of p53, p110Rb, p16, p21, p56Rb, p94Rb, Rb56, and a functional variant of the Rb gene and the p53 gene.

64. (New) The method of claim **63**, wherein said tumor suppressor gene is a functional variant of the Rb gene and the p53 gene.

65. (New) The method of claim **61**, wherein said administration of said compound of Formula I is prior to the administration of said recombinant viral vector.

66. (New) The method of claim **61**, wherein said administration of said compound of Formula I is concomitant with the administration of said recombinant viral vector.

67. (New) The method of claim **61**, wherein the administration of said compound of Formula I further comprises a solubilizing agent.

68. (New) The method of claim **61**, wherein R is a cationic group selected from the group consisting of NMe_3^+ and NH_3^+.

69. (New) The method of claim **61**, wherein the saccharide group comprises one or more pentose or hexose residues.

70. (New) The method of claim **61**, wherein the saccharide group is selected from the group consisting of pentose monosaccharide groups, hexose monosaccharide groups, pentose-pentose disaccharide groups, hexose-hexose disaccharide groups, pentose-hexose disaccharide groups, and hexose-pentose disaccharide groups.

71. (New) The method of claim **61**, wherein the saccharide group comprises between three and about eight monosaccharide residues.

72. (New) The method of claim **61**, wherein the saccharide group is a trisaccharide.

73. (New) The method of claim **61**, wherein at least one of X_2 and X_3 is a saccharide group.

74. (New) The method of claim **61**, wherein m and n are each independently 2 or 3.

75. (New) The method of claim **61**, wherein X_1 and X_2 are both



;

and X_3 is a saccharide group.

76. (New) The method of claim **61**, wherein said compound has Formula III:



III.

77. (New) The method of claim **61**, wherein said compound has Formula IV:



IV.

78. (New) The method of claim **61**, wherein said compound has Formula V:



V.

79. (New) The method of claim **61**, wherein said compound has Formula II:



II

wherein X_1 and X_2 are selected from the group consisting of a



and



;

and X_3 is a saccharide group.

Cancel

80. (New) The method of claim **61**, wherein X_1 and X_2 are both



and X_3 is a glucose group.

81. (New) A method for treating bladder cancer by the administration of a recombinant viral vector encoding a cytostatic or a tumor suppressor gene in combination with a compound of Formula III: